Bruce J. Baum

Bruce J. Baum

Auto-generated profile, based on publicly available information

Bruce J. Baum

Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, NIH, DHHS, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AVAntonis Voutetakis
Antonis Voutetakis
MKM.R. Kok
M.R. Kok
CZChangyu Zheng
Changyu Zheng
IBIoannis Bossis
Ioannis Bossis
JWJianghua Wang
Jianghua Wang
BBBruce J. Baum
Bruce J. Baum
The use of critical-for-life organs (e.g., liver or lung) for systemic gene therapeutics can lead to serious safety concerns. To circumvent such issues, we have considered salivary glands (SGs) as an alternative gene therapeutics target tissue. Given the high secretory abilities of SGs, we hypothesized that administration of low doses of recombinant adeno-associated virus (AAV) vectors would allow for therapeutic levels of transgene-encoded secretory proteins in the bloodstream. We administered 10(9) particles of an AAV vector encoding human erythropoietin (hEPO) directly to individual mouse submandibular SGs. Serum hEPO reached maximum levels 8-12 weeks after gene delivery and remained relatively stable for 54 weeks (longest time studied). Hematocrit levels were similarly increased. Moreover, these effects proved to be vector dose-dependent, and even a dosage as low as 10(8) particles per animal led to significant increases in hEPO and hematocrit levels. Vector DNA was detected only within the targeted SGs, and levels of AAV copies within SGs were highly correlated with serum hEPO levels (r = 0.98). These results show that SGs appear to be promising targets with potential clinical applicability for systemic gene therapeutics.

1 May 1988 in The Journal of the American Dental Association
Verified
Journal Article
Closed access
PFPhilip C. Fox
Philip C. Fox
AWAndy Wolff
Andy Wolff
CYChih-Ko Yeh
Chih-Ko Yeh
JAJane C. Atkinson
Jane C. Atkinson
BBBruce J. Baum
Bruce J. Baum

1 March 2004 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JVJoseph M. Vitolo
Joseph M. Vitolo
ACAna P. Cotrim
Ana P. Cotrim
ASAnastasia L. Sowers
Anastasia L. Sowers
ARAngelo Russo
Angelo Russo
RWRobert B. Wellner
Robert B. Wellner
BBBruce J. Baum
Bruce J. Baum
Purpose: Radiotherapy is commonly used to treat a majority of patients with head and neck cancers. The long-term radiation-induced reduction of saliva output significantly contributes to the posttreatment morbidity experienced by these patients. The purpose of this study was to test the ability of the stable-free radical Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl), an established radioprotector, to prevent radiation-induced salivary hypofunction in mice. Experimental Design: The heads of C3H mice were exposed to a range of single radiation doses with or without an i.p. injection of 275 mg/kg Tempol 10 min before treatment. Salivary gland output was assessed 8 weeks postirradiation. Results: Radiation caused a dose-dependent reduction in salivary flow in this model. Tempol treatment alone significantly reduced radiation-induced salivary hypofunction. The combination of Tempol with mouth/nose shielding showed essentially complete radiation protection at 15 Gy and ∼75% protection at 17.5 Gy. Conclusions: This study demonstrates for the first time that significant radioprotection of the salivary glands is possible with Tempol in C3H mice.

30 September 2010 in Gene Therapy
Verified
Journal Article
Open access
PDF file
RGR Gao
R Gao
XYX Yan
X Yan
CZC Zheng
C Zheng
CGC M Goldsmith
C M Goldsmith
SAS Afione
S Afione
SWSonglin Wang
Songlin Wang
Previously (Shan et al, 2005), we reported that adenoviral vector-mediated transfer of the human aquaporin-1 (hAQP1) cDNA to minipig parotid glands following irradiation (IR) transiently restored salivary flow to near normal levels. This study evaluated a serotype 2, adeno-associated viral (AAV2) vector for extended correction of IR (single dose; 20 Gy)-induced, parotid salivary hypofunction in minipigs. At 16 weeks following the IR parotid salivary flow decreased by 85–90%. AAV2hAQP1 administration at week 17 transduced only duct cells and resulted in a dose-dependent increase in salivary flow to ∼35% of pre-IR levels (to ∼1 ml per 10 min) after 8 weeks (peak response). Administration of a control AAV2 vector or saline was without effect. Little change was observed in clinical chemistry and hematology values after AAV2hAQP1 delivery. Vector-treated animals generated high anti-AAV2 neutralizing antibody titers by week 4 (∼1:1600) and significant elevations in salivary (∼15%), but not serum, granulocyte macrophage colony-stimulating factor levels. Following vector administration, salivary [Na+] was dramatically increased, from ∼10 to ∼55 mM (at 4 weeks) and finally to 39 mM (8 weeks). The findings demonstrate that localized delivery of AAV2hAQP1 to IR-damaged parotid glands leads to increased fluid secretion from surviving duct cells, and may be useful in providing extended relief of salivary hypofunction in previously irradiated patients.

1 August 2006 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
BBBruce J. Baum
Bruce J. Baum
CZChangyu Zheng
Changyu Zheng
ACAna P. Cotrim
Ana P. Cotrim
CGCorinne M. Goldsmith
Corinne M. Goldsmith
JAJane C. Atkinson
Jane C. Atkinson
GIGabor G. Illei
Gabor G. Illei

1 January 2010 in Oral Oncology
Verified
Journal Article
Closed access
BBBruce J. Baum
Bruce J. Baum
CZChangyu Zheng
Changyu Zheng
IAIlias Alevizos
Ilias Alevizos
ACAna P. Cotrim
Ana P. Cotrim
SLShuying Liu
Shuying Liu
GIGabor G. Illei
Gabor G. Illei